ArticleJournal of mass spectrometry and advances in the clinical lab2025
A Label-Free blocking immunoassay to evaluate Anti-Adalimumab antibody activity in clinical samples.
Article in Journal of mass spectrometry and advances in the clinical lab, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Adalimumab (ADL), a monoclonal antibody targeting TNF-⍺, is widely used to treat autoimmune diseases, but its efficacy can diminish over time due to the development of antidrug antibodies (ADAs), particularly neutralizing or blocking ADAs. Immunoassays used for mAb drug TDM typically measure ADA concentrations rather than their functional impact. This article describes an attempt to establish a label-free blocking immunoassay (LF-BIA) to measure the ADA blocking activity in serum samples. Methods: The LF-BIA was designed to measure the ADA blocking activity against the interaction between ADL and its therapeutic target, TNF-⍺. The complete time course of ADL-ADAs and ADL-TNF-⍺ immune complex formation on each sensing probe was recorded as a sensorgram, and an ADA blocking rate was calculated from the sensorgram. Results: The LF-BIA detected ADA blocking activity in serum samples. A 1:25 dilution was selected to determine ADA blocking activity, and 42 patient samples were analyzed. The LF-BIA results showed partial concordance with ELISA results, likely reflecting methodological differences: LF-BIA measures blocking ADAs, whereas ELISA quantifies total ADAs. Conclusions: The LF-BIA may provide an efficient approach to specifically measure blocking ADAs rather than total ADAs. Alongside with previously reported applications of label-free immunoassays in clinical testing, the LF-BIA highlights a promising area in which label-free technologies such as BLI can play an important role.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.